Processa Pharmaceuticals Competitors
| PCSA Stock | USD 3.16 0.04 1.28% |
Processa Pharmaceuticals vs Citius Pharmaceuticals Correlation View
Poor diversification
For the present investment horizon, the measured correlation between PCSA and CTXR stands at 0.77, or Poor diversification. The overlap area represents the portion of risk that may be diversified away when both instruments are held together and nothing else in the portfolio changes.
Moving together with Processa Stock
| 0.73 | DWTX | Dogwood Therapeutics | PairCorr |
| 0.73 | INTS | Intensity Therapeutics | PairCorr |
| 0.63 | IRON | Disc Medicine | PairCorr |
Moving against Processa Stock
Mean reversion in Processa Pharmaceuticals is more reliable over longer time horizons. Short-term deviations can persist and even widen before correcting, making position sizing and risk management critical.
Processa Pharmaceuticals Competition Correlation Matrix
Correlation analysis between Processa Pharmaceuticals and its competitors helps investors understand whether diversification is real or only superficial inside the same peer group. A reading near +1 usually means prices have moved in tandem, a reading near -1 suggests opposite movement, and a reading near zero points to weaker historical dependence.
High positive correlations
| High negative correlations
|
Risk-Adjusted Indicators
There is a big difference between Processa Stock performing well and Processa Pharmaceuticals Company doing well as a business compared to the competition. A thorough review of Processa Pharmaceuticals' risk-adjusted indicators provides a clearer picture of whether returns are being earned efficiently. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.| Mean Deviation | Jensen Alpha | Sortino Ratio | Treynor Ratio | Semi Deviation | Expected Shortfall | Potential Upside | Value @Risk | Maximum Drawdown | ||
|---|---|---|---|---|---|---|---|---|---|---|
| BCTX | 5.30 | -0.76 | 0.00 | 3.19 | 0.00 | 7.66 | 98.43 | |||
| CRIS | 3.54 | -0.41 | 0.00 | -0.33 | 0.00 | 6.48 | 22.66 | |||
| ENTO | 7.46 | 0.04 | 0.00 | -0.03 | 0.00 | 16.86 | 39.61 | |||
| LPTX | 14.85 | 6.53 | 0.65 | -3.91 | 6.90 | 25.00 | 65.13 | |||
| PALI | 4.94 | 0.13 | 0.02 | 0.18 | 5.67 | 11.18 | 31.35 | |||
| HOTH | 2.91 | -0.13 | 0.00 | -0.21 | 0.00 | 7.00 | 20.14 | |||
| MBRX | 4.58 | -0.77 | 0.00 | -0.31 | 0.00 | 7.73 | 56.02 | |||
| ATHA | 5.04 | 1.39 | 0.28 | 3.25 | 4.00 | 9.87 | 72.52 | |||
| ALLR | 3.84 | 0.21 | 0.06 | -0.39 | 4.11 | 8.43 | 29.05 | |||
| CTXR | 4.53 | -0.28 | 0.00 | -0.19 | 0.00 | 10.81 | 27.98 |
Peer Comparison: Net Income
Net income is one of the most important fundamental items in finance. It plays a large role in Processa Pharmaceuticals financial statement analysis. It represents the amount of money remaining after all of Processa Pharmaceuticals operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.Compare Processa Pharmaceuticals and related stocks such as Briacell Therapeutics, Curis Inc, and Entero Therapeutics Net Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| BCTX | -8.6 K | -999 K | -382 K | -8.9 M | -3.5 M | -2.2 M | -3.2 M | -5.4 M | -5.8 M | -4.9 M | -17.6 M | -34.1 M | -27.3 M | -6.5 M | -36.5 M | -32.8 M | -31.2 M |
| CRIS | -12.1 M | -9.9 M | -16.4 M | -12.3 M | -18.7 M | -59 M | -60.4 M | -53.3 M | -32.6 M | -32.1 M | -29.9 M | -45.4 M | -60.3 M | -47.4 M | -43.4 M | -49.9 M | -52.4 M |
| PALI | -1.7 M | -12.5 M | -10.1 M | -19.8 M | -22.6 M | -20.9 M | -21.1 M | -15.7 M | -4.9 M | -8.4 M | -10.3 M | -26.6 M | -14.3 M | -12.3 M | -14.4 M | -13 M | -13.6 M |
| HOTH | -2 M | -2 M | -2 M | -2 M | -2 M | -2 M | -2 M | -2 M | -2.5 M | -7.7 M | -7.2 M | -14.3 M | -11.4 M | -7.8 M | -8.2 M | -7.4 M | -7.7 M |
| MBRX | -748.4 K | -748.4 K | -748.4 K | -748.4 K | -748.4 K | -748.4 K | -3.9 M | -9.8 M | -11.9 M | -13.2 M | -17.4 M | -15.9 M | -29 M | -29.8 M | -21.8 M | -19.6 M | -20.6 M |
| ALLR | -81.2 K | -81.2 K | -81.2 K | -81.2 K | -68.7 K | -1.1 M | -3.7 M | -4.9 M | -2.3 M | -14.3 M | -6.6 M | -26.6 M | -16.1 M | -11.9 M | -24.5 M | -22.1 M | -21 M |
| CTXR | -26.3 K | -22 K | -31.4 K | -1.3 M | -2.9 M | -8.3 M | -10.4 M | -12.5 M | -15.6 M | -17.5 M | -23.1 M | -33.6 M | -32.5 M | -39.1 M | -37.4 M | -33.7 M | -32 M |
Processa Pharmaceuticals Competitive Analysis
How does Processa Pharmaceuticals measure up against Briacell Therapeutics, Curis, and Entero Therapeutics? The financials tell a nuanced story. The company holds a 7.2 M market capitalization. Processa Pharmaceuticals posts a -270.74% return on equity, reflecting current earnings headwinds. Market capitalization diverges sharply here: 31.5 M versus 7.2 M, giving Briacell Therapeutics a clear size advantage. Processa Pharmaceuticals leads with -270.74% return on equity versus -2951.24% for Curis. Return on equity favors Entero Therapeutics at -24.28%, well ahead of Processa Pharmaceuticals at -270.74%.| Better Than Average | Worse Than Peers | View Performance Chart |
Processa Pharmaceuticals Competition Peer Performance Charts
How to Analyze Processa Pharmaceuticals Against Peers
Processa Pharmaceuticals' peer analysis compares Processa Pharmaceuticals with related companies to put valuation, quality, and risk metrics in context. This helps determine whether recent performance is company-specific or broadly sector-driven. A practical workflow includes:- Set a relevant peer group: Include direct competitors and close alternatives with comparable business exposure.
- Benchmark core financials: Compare profitability, growth, capital structure, and cash flow quality.
- Check valuation dispersion: Review whether Processa Pharmaceuticals trades at a premium or discount versus peers and why.
- Evaluate risk profile: Compare volatility, drawdowns, and correlation to avoid false diversification assumptions.
- Document the thesis: Record where Processa Pharmaceuticals leads or lags and what catalysts could close or widen the gap.
Peer Comparison Metrics & Methodology
Short interest comparison for Processa Pharmaceuticals and its peers can highlight which companies in the group are attracting the most skepticism from market participants. The peer set can help frame whether recent outperformance is broad-based or company-specific. For peer comparison, Processa Pharmaceuticals has a market cap of 7.16 M.
The analytics block for Processa Pharmaceuticals relies on periodic company reporting and market reference feeds, with quality checks and normalization applied before rendering. Where analyst coverage exists, consensus estimates are factored in. Timing can vary by data vendor.